Equivalent price position
No other current listing with the same generic, strength, dosage form and compatible unit basis is available for comparison.
Price-position comparison uses current official listed prices normalized to compatible units. It is a price benchmark, not a measure of sales, demand, prescription volume or market share.
Product details
- Generic
- Glucose anhydrous
- Therapeutic area
- Fluids & supportive care
- Drug class
- Fluids, electrolytes & diluents
- ATC
- B05BA
- Strength
- 50 mg/mL
- Dosage form
- IV infusion
- Pack
- 500ml(without Eurocap)
- Registration no.
- 110831
- Price record verified
- 2026-08-09
- Latest DRAP source check
- 2026-10-09 03:22
Manufacturer
Explore this manufacturer's complete MedInfoBase portfolio, generics and current listed prices.
View company portfolio →About Laksol-5 50 mg/mL IV infusion
Laksol-5 50 mg/mL IV infusion contains Glucose anhydrous 50 mg/mL. It is registered with DRAP by Lakhani Pharma (Pvt.) Limited (registration no. 110831). Its official price is PKR 111.52 for a pack of 500ml(without Eurocap). This price has applied since 12 May 2026. Laksol-5 is also available as 5% IV infusion. No other brand of Glucose anhydrous 50 mg/mL in this form is listed in Pakistan.
Other strengths of Laksol-5
Official price over time
No change in the official DRAP price is recorded for this pack (500ml(without Eurocap)). Current price PKR 111.52, effective 12 May 2026.
Cite this price history
MedInfoBase. Laksol-5 50 mg/mL, 500ml(without Eurocap): official price history (source: DRAP PharmaPrice Index). https://medinfobase.com/brand/laksol-5-50-mg-ml-110831-500mlwithout-eurocap-lakhani-pharma-pvt-limited/ (accessed 9 October 2026).
Official price history
| Amount | Effective from | Verified | Source | Status |
|---|---|---|---|---|
| PKR 111.52 | 2026-05-12 | 2026-08-09 | DRAP PharmaPrice Index | Current |
Other listed brands
Cite this record
Medicine record · DRAP registration 110831Price and registration data on this page were observed on 9 August 2026. Records change over time, so please cite the observation date alongside the access date.
